RxDoctor Payments Data

Monica Ertel

Glaucoma Specialist · Aurora, CONPI 1669869707

Payments from drug & device makers

What this record shows

11 manufacturers reported payments, led by AbbVie at 51.4% of the total. Reporting peaked in 2022 at $3,730 and has fallen 85.2% since, to $553 in 2025.

$7,121in general payments, 2019–2025

Across 55 payments — averaging $129.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • NEW World Medical,inc.$1K
  • Alcon$835
  • Johnson & Johnson Surgical Vision, Inc.$356
  • Sight Sciences, Inc.$272
  • Aerie Pharmaceuticals, Inc.$248
  • plus $257 from 5 others

What the payments were for

  • Consulting fees$3,20645%
  • Food & beverage$3,91555%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$232,940
Medicare patients
654
Services billed
2,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost146$78,028
RhopressaNetarsudil Mesylate84$50,308
RestasisCyclosporine16$20,430
Alphagan PBrimonidine Tartrate38$19,074
Prednisolone Acetate343$11,868
ZioptanTafluprost/Pf24$9,787
Brimonidine Tartrate282$9,324
Latanoprost854$9,225
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat426$7,754
SimbrinzaBrinzolamide/Brimonidine Tart23$6,852
CombiganBrimonidine Tartrate/Timolol14$6,677
Ketorolac Tromethamine269$6,214
Dorzolamide-TimololDorzolamide/Timolol/Pf21$5,742
VyzultaLatanoprostene Bunod12$5,651
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$3,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$3,662$124,209214 claims
Aerie Pharmaceuticals, Inc.Rhopressa$248$50,30884 claims
AlconSimbrinza$835$6,85223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →